Perhexiline

DRUG8 trials

Conditions

Cardiac Output, LowCardiomyopathy, HypertrophicCardiomyopathy, Hypertrophic, FamilialChronic Heart FailureDiabetic CardiomyopathyDiastolic Heart FailureHypertrophic CardiomyopathyHypertrophy, Left Ventricular

Phase 1

Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes

NCT00628056

University Hospital BirminghamDiabetic Cardiomyopathy

Start: 2006-10-31End: 2009-04-30Target: 75Updated: 2008-03-04

Phase 2

Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome

CompletedNCT00839228

University of AberdeenDiastolic Heart Failure

Start: 2009-03-31End: 2014-02-28Target: 70Updated: 2015-11-05

Metabolic Manipulation in Chronic Heart Failure

CompletedNCT00841139

University Hospital Birmingham NHS Foundation TrustChronic Heart Failure

Start: 2009-02-28End: 2011-09-30Updated: 2011-11-29

Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery

CompletedNCT00845364

University Hospital BirminghamCardiac Output, Low, Myocardial Reperfusion Injury

Start: 2007-02-28End: 2010-04-30Updated: 2010-05-20

Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy

NCT00989508

University Hospital BirminghamCardiac Output, Low, Hypertrophy, Left Ventricular, Myocardial Reperfusion Injury

Start: 2009-10-31End: 2012-12-31Target: 220Updated: 2011-08-11

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

TerminatedNCT02862600

Heart Metabolics LimitedCardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial

Start: 2016-08-01End: 2017-05-22Updated: 2017-08-31

Role of Perhexiline in Hypertrophic Cardiomyopathy

NCT04426578

Flinders UniversityHypertrophic Cardiomyopathy

Start: 2020-12-01End: 2022-08-01Target: 60Updated: 2021-03-11

Phase 3

Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure

WithdrawnNCT02431221

Heart Metabolics LimitedHypertrophic Cardiomyopathy

Updated: 2017-07-14

Related Papers

Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy.

2015-01-2880 citations

The effect of perhexiline on myocardial protection during coronary artery surgery: a two-centre, randomized, double-blind, placebo-controlled trial

European Journal of Cardio-Thoracic Surgery2014-06-198 citations

Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial.

2011-06-0611 citations